Found vs MEDVi: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

52 providers verified independently·Independent research·How we rank →

MEDVi beats Found overall, scoring 7.7/10 vs 7.3/10. Found is more affordable at $129/mo vs $179/mo. Choose Found for insured patients who want their glp-1 coverage checked and t. Choose MEDVi for users who want a low entry price with oral and injectable co.

A side-by-side look at Found and MEDVi to help you decide. We compare them on:

•Starting price per month
•Our overall score, out of 10
•Medication type, brand-name or compounded
•Whether they accept insurance
•Who each one is best for

Found

#36 of 52

7.3/10

Science-backed weight management platform combining GLP-1 medications with behavioral health coaching and support.

Visit Found

Higher Rated

MEDVi

#20 of 52

7.7/10

MEDVi is a compounded GLP-1 telehealth platform offering both oral tablets and injectable semaglutide and tirzepatide, with micro-dosing options for side-effect-sensitive patients. $179/mo entry pricing, free shipping, and a streamlined intake, one of the broader compounded mixes among independent telehealth providers in 2026.

Visit MEDVi

Feature	Found	MEDVi
Our Score	7.3/10	7.7/10
Starting Price	$129/mo	$179/mo
Medication Type	Both	Both
Insurance Accepted	Yes	No
Best For	Insured patients who want their GLP-1 coverage checked and their copay minimized	Users who want a low entry price with oral and injectable compounded options
Ranking	#36	#20
Get started	Visit Found	Visit MEDVi

Pros & Cons Compared

Found

Pros

+Active insurance coordination, Found contacts your insurer and reports which GLP-1s are covered, prior auth requirements, and estimated copay
+10+ medication options including both compounded and brand-name (Wegovy, Zepbound, Wegovy pill), the widest formulary of any platform
+Typical insured copay of ~$30/mo for most members, dramatically lower than cash-pay alternatives
+Most members start treatment within one week of completing the health questionnaire

Cons

−Costs vary by insurance status and medication choice rather than one flat rate; run Found's coverage check first to see your exact copay before paying
−The insurance navigation process adds steps compared to simple cash-pay platforms; the payoff is the ~$30 typical copay
−Compounded medication availability may shift with FDA enforcement changes; the 10+ medication formulary lets your clinician move you to a brand-name option if it does

MEDVi

Pros

+One of the few compounded providers offering both oral tablets and injectable semaglutide
+Micro-dosing options available, can start at sub-standard doses for patients concerned about side effects
+Sleek onboarding experience with clear progress tracking through their patient portal
+$179/mo is competitive for a platform with both oral and injectable compounded formulations

Cons

−No brand-name Wegovy or Zepbound on the platform (the 2026 expansion added branded Ozempic only)
−No insurance accepted, and oral compounded semaglutide has less clinical data than injectable forms; you can switch to injectable anytime at no extra fee if results lag

Our Verdict

MEDVi edges out Found with a score of 7.7/10 vs 7.3/10. If budget is your priority, Found starts at $129/mo compared to MEDVi's $179/mo. Found accepts insurance, which can significantly reduce your out-of-pocket costs. Choose Found if you want: insured patients who want their glp-1 coverage checked and their copay minimized. Choose MEDVi if you want: users who want a low entry price with oral and injectable compounded options.

Still undecided? Editor's Featured Pick

Yucca Health

$146/mo · 7.7/10 · Compounded

If neither Found nor MEDVi feels like the right fit, our featured pick across all 52 GLP-1 telehealth providers is Yucca Health. It is not the highest-scored provider in our full rankings. We feature it for its low-friction value: a flat $146/mo that stays the same at every dose.

Visit Yucca Health→Read our full Yucca Health review